Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Other Operating Expenses (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Other Operating Expenses for 5 consecutive years, with -$2.5 million as the latest value for Q1 2026.

  • For Q1 2026, Other Operating Expenses fell 15.69% year-over-year to -$2.5 million; the TTM value through Mar 2026 reached -$9.9 million, down 7.56%, while the annual FY2025 figure was -$9.6 million, 5.86% down from the prior year.
  • Other Operating Expenses hit -$2.5 million in Q1 2026 for Bicycle Therapeutics, up from -$2.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at -$1.9 million in Q2 2024 and bottomed at -$2.6 million in Q4 2024.
  • Average Other Operating Expenses over 3 years is -$2.4 million, with a median of -$2.5 million recorded in 2025.
  • On a YoY basis, Other Operating Expenses climbed as much as 2.29% in 2025 and fell as far as 21.45% in 2025.
  • Bicycle Therapeutics' Other Operating Expenses stood at -$2.6 million in 2024, then changed by 0.0% to -$2.6 million in 2025, then grew by 1.82% to -$2.5 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$2.5 million, -$2.6 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.